Kuojun E. Zhang

Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition.

Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition.

Journal: Journal of medicinal chemistry
Published: June 22, 2026

Induced proximity strategies for modulating immune checkpoints in cancer immunotherapy.

Induced proximity strategies for modulating immune checkpoints in cancer immunotherapy.

Journal: European journal of medicinal chemistry
Published: March 12, 2026

Dual PARP/NAMPT Inhibitors for BRCA Wild-Type Triple-Negative Breast Cancer: Disrupting Homologous Recombination Repair and Activating Antitumor Immunity.

Dual PARP/NAMPT Inhibitors for BRCA Wild-Type Triple-Negative Breast Cancer: Disrupting Homologous Recombination Repair and Activating Antitumor Immunity.

Journal: Journal of medicinal chemistry
Published: January 17, 2026

Targeting HPK1 for cancer immunotherapy: An update on recent medicinal chemistry advances.

Targeting HPK1 for cancer immunotherapy: An update on recent medicinal chemistry advances.

Journal: Bioorganic & medicinal chemistry
Published: November 20, 2025

Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy.

Discovery of a Novel Potent and Orally Efficacious PROTAC Degrader of HPK1 for Tumor Immunotherapy.

Journal: Journal of medicinal chemistry
Published: July 30, 2025

Discovery, Synthesis, and Activity Evaluation of Novel Small-Molecule Inhibitors Targeting VISTA for Cancer Immunotherapy.

Discovery, Synthesis, and Activity Evaluation of Novel Small-Molecule Inhibitors Targeting VISTA for Cancer Immunotherapy.

Journal: Journal of medicinal chemistry
Published: February 27, 2025

Discovery of dual PARP/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer.

Discovery of dual PARP/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer.

Journal: Bioorganic & medicinal chemistry letters
Published: December 21, 2024

Discovery of 1,2,4-benzotriazine derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.

Discovery of 1,2,4-benzotriazine derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.

Journal: Bioorganic chemistry
Published: October 25, 2024

Discovery of Benzo[d]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway.

Discovery of Benzo[d]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway.

Journal: Journal of medicinal chemistry
Published: October 10, 2024

Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins.

Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins.

Journal: European journal of medicinal chemistry
Published: August 08, 2024

Discovery of novel phenyl urea SHP2 inhibitors with anti-colon cancer and potential immunomodulatory effects.

Discovery of novel phenyl urea SHP2 inhibitors with anti-colon cancer and potential immunomodulatory effects.

Journal: European journal of medicinal chemistry
Published: June 30, 2024

Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b).

Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b).

Journal: Journal of medicinal chemistry
Published: January 05, 2024
Showing 1-12 of 38

Last Updated: 09/26/2026